Details of the Drug

General Information of Drug (ID: DMVEK07)

Drug Name
Magnesium Sulfate
Synonyms
Magnesiumsulfat; Bitter salt; Epsom salt; Hair salt; Heptahydrate Magnesium Sulfate; Kieserite [as monohydrate]; Magnesium Sulfate In Plastic Container; Magnesium Sulphate Hydrate; Magnesium bisulfate; Magnesium hydrogensulphate; Magnesium sulfate anhydrous; Magnesium sulfate dried; Magnesium sulfate hexahydrate; Magnesium sulfate solution; Magnesium sulphate; Sal Angalis; Sal De sedlitz; Sal amarum; Sal anglicum; Sal catharticum; Sal seidlitense; Salts of england; Sulfuric acid magnesium salt; Tomix OT; MgSO4; Epsom Sa (TN); Magnesium Sulfate, Heptahydrate; Magnesium sulfate in dextrose 5% in plastic container; Magnesium(II) sulfate; OT-S; Sel d'angleterre; Sulfate, Magnesium; Sulfuric acid magnesium salt (VAN); Sulfuric acid, magnesium salt; Magnesium sulfate (1:1); Magnesium(2+) ion sulfate; OT-S (drying agent); SDA 15-062-07; Sulfuric acid magnesium salt (1:1); Sulfuric acid, C10-16 alkyl ester, magnesium salt; Sulfuric acid, magnesium salt (1:1); Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts; (C10-C16) Alkylalcohol sulfuric acid, magnesium salt
Indication
Disease Entry ICD 11 Status REF
Acute pain MG31 Approved [1]
Familial primary hypomagnesemia N.A. Approved [2]
Hypertension, pregnancy-induced N.A. Approved [2]
Mild pre-eclampsia N.A. Approved [2]
Non-arteritic anterior ischemic optic neuropathy 9C40.40 Approved [2]
Pain MG30-MG3Z Approved [2]
Severe pre-eclampsia N.A. Approved [2]
Traumatic brain injury NA07.Z Approved [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Analgesics
Affected Organisms
Humans and other mammals
ATC Code
A06AD04: Magnesium Sulfate
A06AD: Osmotically acting laxatives
A06A: DRUGS FOR CONSTIPATION
A06: DRUGS FOR CONSTIPATION
A: ALIMENTARY TRACT AND METABOLISM
A12CC02: Magnesium Sulfate
A12CC: Magnesium
A12C: OTHER MINERAL SUPPLEMENTS
A12: MINERAL SUPPLEMENTS
A: ALIMENTARY TRACT AND METABOLISM
B05XA05: Magnesium Sulfate
B05XA: Electrolyte solutions
B05X: I.V. SOLUTION ADDITIVES
B05: BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B: BLOOD AND BLOOD FORMING ORGANS
D11AX05: Magnesium Sulfate
D11AX: Other dermatologicals
D11A: OTHER DERMATOLOGICAL PREPARATIONS
D11: OTHER DERMATOLOGICAL PREPARATIONS
D: DERMATOLOGICALS
V04CC02: Magnesium Sulfate
V04CC: Tests for bile duct patency
V04C: OTHER DIAGNOSTIC AGENTS
V04: DIAGNOSTIC AGENTS
V: VARIOUS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 120.37
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 4
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 43.2 hours (in newborns) [3]
Chemical Identifiers
Formula
MgO4S
IUPAC Name
magnesium;sulfate
Canonical SMILES
[O-]S(=O)(=O)[O-].[Mg+2]
InChI
InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
InChIKey
CSNNHWWHGAXBCP-UHFFFAOYSA-L
Cross-matching ID
PubChem CID
24083
ChEBI ID
CHEBI:32599
CAS Number
7487-88-9
UNII
ML30MJ2U7I
DrugBank ID
DB00653
TTD ID
D02LDN
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Antagonist [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Gene/Protein Processing [5]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Gene/Protein Processing [5]
Kallikrein-8 (KLK8) OTGVGHXY KLK8_HUMAN Gene/Protein Processing [6]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Magnesium Sulfate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Sarecycline . Acne vulgaris [ED80] [8]
Framycetin DMF8DNE Major Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Framycetin. Alcoholic liver disease [DB94] [9]
Nifedipine DMSVOZT Moderate Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Nifedipine. Angina pectoris [BA40] [10]
Ofloxacin DM0VQN3 Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Ofloxacin. Bacterial infection [1A00-1C4Z] [11]
Kanamycin DM2DMPO Major Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Kanamycin. Bacterial infection [1A00-1C4Z] [9]
Trovafloxacin DM6AN32 Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Trovafloxacin. Bacterial infection [1A00-1C4Z] [11]
Sparfloxacin DMB4HCT Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Sparfloxacin. Bacterial infection [1A00-1C4Z] [11]
Streptomycin DME1LQN Major Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Streptomycin. Bacterial infection [1A00-1C4Z] [9]
Gemifloxacin DMHT34O Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Gemifloxacin. Bacterial infection [1A00-1C4Z] [11]
Norfloxacin DMIZ6W2 Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Norfloxacin. Bacterial infection [1A00-1C4Z] [11]
ABT-492 DMJFD2I Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by ABT-492. Bacterial infection [1A00-1C4Z] [11]
Gentamicin DMKINJO Major Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Gentamicin. Bacterial infection [1A00-1C4Z] [9]
Omadacycline DMR2J95 Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Omadacycline. Bacterial infection [1A00-1C4Z] [8]
Netilmicin DMRD1QK Major Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Netilmicin. Bacterial infection [1A00-1C4Z] [9]
Levofloxacin DMS60RB Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Levofloxacin. Bacterial infection [1A00-1C4Z] [11]
Tobramycin DMUI0CH Major Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Tobramycin. Bacterial infection [1A00-1C4Z] [9]
Minocycline DMVN5OH Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Minocycline. Bacterial infection [1A00-1C4Z] [8]
Lomefloxacin DMVRH9C Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Lomefloxacin. Bacterial infection [1A00-1C4Z] [11]
Tetracycline DMZA017 Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Tetracycline. Bacterial infection [1A00-1C4Z] [8]
Etidronic acid DM1XHYJ Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Etidronic acid. Bone paget disease [FB85] [12]
Risedronate DM5FLTY Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Risedronate. Bone paget disease [FB85] [13]
Doxercalciferol DM6FG1P Moderate Increased risk of hypermagnesemia by the combination of Magnesium Sulfate and Doxercalciferol. Chronic kidney disease [GB61] [14]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Atracurium. Corneal disease [9A76-9A78] [15]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Mivacurium. Corneal disease [9A76-9A78] [15]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Pancuronium. Corneal disease [9A76-9A78] [15]
Dolutegravir DMCZGRE Major Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Dolutegravir. Human immunodeficiency virus disease [1C60-1C62] [16]
Raltegravir DMYURI6 Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Raltegravir. Human immunodeficiency virus disease [1C60-1C62] [17]
Paricalcitol DMYBV3G Moderate Increased risk of hypermagnesemia by the combination of Magnesium Sulfate and Paricalcitol. Hyper-parathyroidism [5A51] [14]
Levamlodipine DM92S6N Moderate Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Levamlodipine. Hypertension [BA00-BA04] [10]
Felodipine DMOSW35 Moderate Additive hypotensive effects by the combination of Magnesium Sulfate and Felodipine. Hypertension [BA00-BA04] [10]
Clevidipine butyrate DMW4M97 Moderate Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Clevidipine butyrate. Hypertension [BA00-BA04] [10]
Baloxavir marboxil DM1UV7F Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Baloxavir marboxil. Influenza [1E30-1E32] [18]
Ibandronate DM0QZBN Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Ibandronate. Low bone mass disorder [FB83] [19]
Dihydrotachysterol DMFB97P Moderate Increased risk of hypermagnesemia by the combination of Magnesium Sulfate and Dihydrotachysterol. Mineral deficiency [5B5K] [14]
Gatifloxacin DMSL679 Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Gatifloxacin. Respiratory infection [CA07-CA4Z] [11]
Penicillamine DM40EF6 Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Penicillamine. Rheumatoid arthritis [FA20] [20]
Deferiprone DMS2M7O Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Deferiprone. Thalassaemia [3A50] [21]
Eltrombopag DMOGFIX Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Eltrombopag. Thrombocytopenia [3B64] [22]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Vecuronium. Tonus and reflex abnormality [MB47] [15]
Rocuronium DMY9BMK Moderate Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Rocuronium. Tonus and reflex abnormality [MB47] [15]
Cinoxacin DM4EWNS Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Cinoxacin. Urinary tract infection [GC08] [11]
Plazomicin DMKMBES Major Additive neuromuscular blocking effects by the combination of Magnesium Sulfate and Plazomicin. Urinary tract infection [GC08] [9]
Nalidixic acid DMRM0JV Moderate Decreased absorption of Magnesium Sulfate due to formation of complexes caused by Nalidixic acid. Urinary tract infection [GC08] [23]
⏷ Show the Full List of 43 DDI Information of This Drug

References

1 Emerging drugs for acute ischemic stroke. Expert Opin Emerg Drugs. 2009 Mar;14(1):33-42.
2 Magnesium Sulfate FDA Label
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Magnesium sulfate diminishes the effects of amide local anesthetics in rat sciatic-nerve block. Reg Anesth Pain Med. 2007 Jul-Aug;32(4):288-95.
5 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
6 Activation and enzymatic characterization of recombinant human kallikrein 8. Biol Chem. 2006 Jun;387(6):723-31. doi: 10.1515/BC.2006.091.
7 Haemodynamic and endocrine effects of deliberate hypotension with magnesium sulphate for cerebral-aneurysm surgery. Eur J Anaesthesiol. 1991 Mar;8(2):115-21.
8 Covington TR, Lawson LC, Young LL, eds. "Handbook of Nonprescription Drugs. 10th ed." Washington, DC: American Pharmaceutical Association (1993):.
9 Piper BJ, Alinea AA, Wroblewski JR, et al. A Quantitative and Narrative Evaluation of Goodman and Gilman's Pharmacological Basis of Therapeutics. Pharmacy (Basel). 2019;8(1):1. Published 2019 Dec 20. [PMID: 31861770]
10 Benami M, Giladi Y, Shalev E "The combination of magnesium sulphate and nifedipine - a cause of neuromuscular blockade." Br J Obstet Gynaecol 101 (1994): 262-3. [PMID: 8193107]
11 Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
12 Product Information. Boniva (ibandronate). Roche Laboratories, Nutley, NJ.
13 Product Information. Bonefos (clodronate). Rhone-Poulenc Rorer Canada Inc, Laval, QC.
14 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
15 Fuchs-Buder T, Wilder-Smith OH, Borgeat A, Tassonyi E "Interaction of magnesium sulphate with vecuronium-induced neuromuscular block." Br J Anaesth 74 (1995): 405-9. [PMID: 7734259]
16 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
17 Canadian Pharmacists Association.
18 Product Information. Xofluza (baloxavir marboxil). Genentech, South San Francisco, CA.
19 Darcy PF "Nutrient-drug interactions." Adverse Drug React Toxicol Rev 14 (1995): 233-54. [PMID: 8845456]
20 Haagsma CJ "Clinically important drug interactions with disease-modifying antirheumatic drugs." Drugs Aging 13 (1998): 281-9. [PMID: 9805209]
21 Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.
22 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
23 Product Information. NegGram (nalidixic acid). Sanofi Winthrop Pharmaceuticals, New York, NY.